VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
MASIMasimo Corporation
$179.95$9.4B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksMASIP/E History

MASI logoMasimo Corporation (MASI) P/E Ratio History

Deep Value

Trading at -64.3x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2007–2026

Current P/E (TTM)
-64.3x
-194% vs 5Y avg
5Y Avg P/E
68.6x
Median 65.3x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
-64.3x
Min39.2xMedian65.3xMax122.3x
TTM EPS$1.45
Price$179.95
Earnings YieldN/A
EPS Growth (1Y)51.0%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 21, 2026, Masimo Corporation (MASI) trades at a price-to-earnings ratio of -64.3x, with a stock price of $179.95 and trailing twelve-month earnings per share of $1.45.

The current P/E is 194% below its 5-year average of 68.6x. Over the past five years, MASI's P/E has ranged from a low of 39.2x to a high of 122.3x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, MASI trades at a 391% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, MASI trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MASI DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

MASI Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-64.3vs22.1
-391%
Below Sector
vs. S&P 500
-64.3vs24.4
-363%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 51% EPS growth (1Y)

MASI P/E vs Peers

Patient monitoring and respiratory care peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
PODD logoPODDInsulet Corporation
$10B41.90.41-40%
HOLX logoHOLXHologic, Inc.
$17B30.5--25%
ITGR logoITGRInteger Holdings Corporation
$3B31.57.15-15%
ICUI logoICUIICU Medical, Inc.
$4B4774.5-+101%
INVA logoINVAInnoviva, Inc.
$2B6.8Lowest0.66+817%Best
NOVT logoNOVTNovanta Inc.
$6B105.632.06-17%
MMSI logoMMSIMerit Medical Systems, Inc.
$4B31.6-+5%
HAYW logoHAYWHayward Holdings, Inc.
$3B22.10.16Best+26%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

MASI Historical P/E Data (2007–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1Apr 04 2026$178.59$1.46122.3x+209%
FY2024 Q3Sep 28 2024$133.20$1.4591.9x+132%
FY2024 Q2Jun 29 2024$125.94$1.4785.7x+116%
FY2024 Q1Mar 30 2024$146.85$1.4799.9x+152%
FY2023 Q4Dec 31 2023$117.21$1.5177.6x+96%
FY2023 Q3Sep 30 2023$87.68$1.6353.8x+36%
FY2023 Q2Jul 01 2023$164.55$2.1377.3x+95%
FY2023 Q1Apr 01 2023$184.54$2.1785.0x+115%
FY2022 Q4Dec 31 2022$147.95$2.5957.1x+44%
FY2022 Q3Oct 01 2022$141.16$3.0246.7x+18%
FY2022 Q2Jul 02 2022$135.90$3.3240.9x+3%
FY2022 Q1Apr 02 2022$151.71$3.8739.2x-1%
FY2021 Q4Dec 31 2021$292.78$3.9873.6x+86%
FY2021 Q3Oct 02 2021$270.46$4.0167.4x+70%
FY2021 Q2Jul 03 2021$252.03$3.8665.3x+65%
FY2021 Q1Apr 03 2021$233.67$3.9459.3x+50%
FY2020 Q4-$268.38$4.1464.8x+64%
FY2020 Q3Sep 26 2020$225.90$3.8558.7x+48%
FY2020 Q2Jun 27 2020$217.50$3.8656.3x+42%
FY2020 Q1Mar 28 2020$179.03$3.6948.5x+22%
FY2019 Q4-$158.06$3.4445.9x+16%
FY2019 Q3Sep 28 2019$146.61$3.3543.8x+10%
FY2019 Q2Jun 29 2019$148.82$3.5142.4x+7%
FY2019 Q1Mar 30 2019$138.28$3.5139.4x-1%
FY2018 Q4Dec 31 2018$107.37$3.4631.0x-22%
FY2018 Q3Sep 29 2018$124.54$2.6447.2x+19%
FY2018 Q2Jun 30 2018$97.65$2.2643.2x+9%
FY2018 Q1Mar 31 2018$87.95$2.2738.7x-2%
FY2017 Q4Dec 31 2017$84.80$2.3835.6x-10%
FY2017 Q3Sep 30 2017$86.56$6.3413.7x-66%
FY2017 Q2Jul 01 2017$91.18$6.2214.7x-63%
FY2017 Q1Apr 01 2017$93.26$5.9915.6x-61%
FY2016 Q4Dec 31 2016$67.40$5.5912.1x-70%
FY2016 Q3Oct 01 2016$59.49$2.0828.6x-28%
FY2016 Q2Jul 02 2016$52.47$1.9227.3x-31%
FY2016 Q1Apr 02 2016$42.47$1.7124.8x-37%
FY2015 Q4-$41.51$1.5626.6x-33%
FY2015 Q3Oct 03 2015$39.26$1.5026.2x-34%
FY2015 Q2Jul 04 2015$38.61$1.4127.4x-31%
FY2015 Q1Apr 04 2015$33.45$1.2925.9x-35%
FY2014 Q4Dec 31 2014$26.34$1.3020.3x-49%
FY2014 Q3Sep 27 2014$21.09$1.0619.9x-50%
FY2014 Q2Jun 28 2014$23.65$1.0622.3x-44%
FY2014 Q1Mar 29 2014$26.62$1.1223.8x-40%
FY2013 Q4-$29.23$1.0128.9x-27%
FY2013 Q3Sep 28 2013$26.53$1.1123.9x-40%
FY2013 Q2Jun 29 2013$21.20$1.0819.6x-50%
FY2013 Q1Mar 30 2013$19.62$1.0818.2x-54%
FY2012 Q4Dec 31 2012$21.01$1.0719.6x-50%
FY2012 Q3Sep 29 2012$24.18$1.0423.3x-41%
FY2012 Q2Jun 30 2012$22.38$1.0421.5x-46%
FY2012 Q1Mar 31 2012$23.38$1.0222.9x-42%
FY2011 Q4Dec 31 2011$18.68$1.0517.8x-55%
FY2011 Q3Oct 01 2011$21.63$1.0820.0x-49%
FY2011 Q2Jul 02 2011$30.20$1.1127.2x-31%
FY2011 Q1Apr 02 2011$33.27$1.0731.1x-22%
FY2010 Q4Dec 31 2010$29.07$1.2124.0x-39%
FY2010 Q3Oct 02 2010$27.87$1.1823.6x-40%
FY2010 Q2Jul 03 2010$23.20$1.1320.5x-48%
FY2010 Q1Apr 03 2010$26.48$1.1123.9x-40%
FY2009 Q4-$30.42$0.8934.2x-14%
FY2009 Q3Oct 03 2009$26.15$0.6540.2x+1%
FY2009 Q2Jul 04 2009$22.70$0.6534.9x-12%
FY2009 Q1Apr 04 2009$29.68$0.6148.6x+23%
FY2008 Q4Dec 31 2008$29.83$0.5455.2x+39%
FY2008 Q3Sep 27 2008$37.41$0.7848.0x+21%
FY2008 Q2Jun 28 2008$34.86$1.1929.3x-26%
FY2008 Q1Mar 29 2008$26.27$1.5217.3x-56%
FY2007 Q4Dec 31 2007$39.45$1.8121.8x-45%
FY2007 Q3Sep 29 2007$25.66$2.3311.0x-72%

Average P/E for displayed period: 39.6x

Export Data
Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into MASI consensus models and risk factors.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

19+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

MASI — Frequently Asked Questions

Quick answers to the most common questions about buying MASI stock.

What is MASI's P/E ratio?

Masimo Corporation (MASI) trailing twelve-month P/E ratio is -64.3x, based on TTM diluted EPS of $1.45. The 5-year average P/E is 68.6x and the historical range spans 39.2x to 122.3x.

Is MASI stock overvalued or undervalued?

MASI trades at -64.3x P/E, below its 5-year average of 68.6x. At the 0th percentile of its historical range (39.2x–122.3x), the stock is priced at a discount to its own history.

Is MASI stock expensive?

No, MASI is not expensive on a historical basis. The current P/E of -64.3x is below the 5-year average of 68.6x and sits at the 0th percentile of its valuation range.

What is MASI's historical P/E range?

Over the past 5 years, MASI's P/E ratio has ranged from 39.2x to 122.3x, with a median of 65.3x and an average of 68.6x. The current P/E of -64.3x places the stock at the 0th percentile of this range. Full historical data spans 2007–2026.

How does MASI's P/E compare to the S&P 500?

MASI trades at -64.3x P/E versus the S&P 500 median of 24.4x. The 364% discount to the market suggests lower growth expectations or perceived higher risk.

How does MASI's valuation compare to Healthcare peers?

Masimo Corporation P/E of -64.3x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is MASI's PEG ratio?

MASI PEG ratio is N/A, based on a P/E of -64.3x and EPS growth of 51.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is MASI's earnings yield?

MASI earnings yield is N/A, the inverse of its -64.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

MASI P/E Ratio History (2007–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current122.3x
Period Avg68.6x
Range39.2x - 122.3x
Change+152%
20 quartersMar 28, 2020 - Apr 4, 2026